NYRADA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.08 AUD | -2.44% |
|
-14.89% | +263.64% |
| Apr. 30 | Nyrada's NYR-BI03 Being Studied For Potential in Traumatic Brain Injury | MT |
| Apr. 18 | Transcript : Nyrada Inc., Q3 2024 Earnings Call, Apr 18, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 1.09 1.66 | Sales 2023 | 1.43 2.17 | Capitalization | 4.37M 6.64M |
|---|---|---|---|---|---|
| Net income 2022 | -3M -4.56M | Net income 2023 | -7M -10.64M | EV / Sales 2022 | 9,367,032 x |
| Net cash position 2022 | 10.82M 16.44M | Net cash position 2023 | 3.71M 5.64M | EV / Sales 2023 | 461,207 x |
| P/E ratio 2022 |
-4.5
x | P/E ratio 2023 |
-0.56
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 30.03% |
More Fundamentals
* Assessed data
More news
Latest transcript on Nyrada Inc.
More press releases
| 1 day | -2.44% | ||
| 1 week | -14.89% | ||
| Current month | -14.89% | ||
| 1 month | -33.33% | ||
| 3 months | +220.00% | ||
| 6 months | +280.95% | ||
| Current year | +263.64% |
1 week
0.08
0.10
1 month
0.080.14
Current year
0.020.17
1 year
0.020.17
3 years
0.020.37
5 years
0.020.46
10 years
0.020.46
| Managers | Title | Age | Since |
|---|---|---|---|
James Bonnar
CEO | Chief Executive Officer | - | 18-01-31 |
| Founder | - | 17-08-28 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | - | 17-08-28 | |
Ruediger Weseloh
BRD | Director/Board Member | - | 19-05-31 |
Marcus Frampton
BRD | Director/Board Member | 44 | 19-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 0.08 | -2.44% | 916,191 |
| 24-05-07 | 0.082 | -9.89% | 1,513,254 |
| 24-05-06 | 0.091 | +1.11% | 125,919 |
| 24-05-03 | 0.09 | -4.26% | 1,189,578 |
| 24-05-02 | 0.094 | +2.17% | 460,132 |
Delayed Quote Australian S.E., May 08, 2024 at 01:59 am EDT
More quotes
Nyrada Inc. is a preclinical stage, drug development company specializing in small molecule drugs to treat cardiovascular and neurological diseases. The Companyâs two lead programs are focused on cholesterol-lowering and brain injury. These programs are developing an oral, small molecule cholesterol-lowering drug, and a drug to reduce secondary brain damage following a stroke or traumatic brain injury (TBI). Its Cholesterol-Lowering Program is an oral PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs. Its Brain Injury Program is developing a drug to block secondary brain damage that occurs following a stroke or TBI, such as severe head trauma from contact sports, a fall, or a motor vehicle accident. The Brain Injury Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischemic stroke. It is also developing new therapies.
Sector
Pharmaceuticals
Calendar
2024-05-15
- Extraordinary Shareholders Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +263.64% | 9.73M | |
| +32.95% | 700B | |
| -4.97% | 358B | |
| +18.83% | 330B | |
| +3.54% | 287B | |
| +15.70% | 236B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| +6.70% | 161B | |
| -1.81% | 157B |
- Stock Market
- Equities
- NYR Stock